The multiplex assays market produced USD 3,918 million revenue in 2023, and it will power at a rate of 9% by the end of this decade, touching USD 7,103.5 million by 2030.
 |
| To learn more about this report: https://bit.ly/4aNVHAn |
The main factor powering the industry is the growing incidence of chronic ailments and infectious diseases. Also, the growing requirement for effective analytical platforms in research and medical diagnostics, to decrease the costs for researchers, healthcare providers, and patients, is a robust contributor.
On the basis of product, the consumables category led the industry with a share, of 45%, in 2023. It was because of the increase in the count of diagnostic tests and surge in research actions by life sciences companies.
For example, in January 2023, Novo Nordisk, a pharma company, publicized a USD 6-million grant for Durham Technical Community College, for supporting the later’s life sciences program and set up a novel training center with area of 35,000 square feet.
The protein-based category led the multiplex assays market, with a 50%, share in 2023, due to the growing applications of these kinds of products in proteomics studies. Furthermore, protein-based assays are extensively used in research to recognize the protein concentration, electrophoresis, cell biology and other analytes.
The flow cytometry category led the industry in 2023, because of the numerous applications of this tech in the discovery and measurement of proteins and RNA and in the assessment of cell health.
For instance, Life Sciences Core Facilities, the Flow Cytometry Unit, Weizmann Institute of Science’s is making the use of imaging flow analyzers that combine the high-amount quantification of flow cytometry with microscopy and aid in the study of post-translational alterations and protein, protein interactions in different contexts.
North America led the industry with a share of 55%, in 2023, and it will power at a considerable rate, as a result of the increase in the research and development activities by biotech and pharma companies for the expansion of new drugs and diagnostic solutions.
For example, in Jan 2023, PharmaEssentia Corporation publicized plans for a new PIRC in Greater Boston, Massachusetts. Likewise, in October 2022, Lineage Cell Therapeutics Inc. publicized the opening of a novel research and development facility in California and the development of its GMP-compliant capability in Israel. Lineage’s novel facility in California will extend its R&D competences in the U.S. and support the expansion of present and future allogeneic cell transplant programs.
It is because of the growing prevalence of chronic and infectious diseases all over the world, the demand for multiplex assays is on the rise. This trend will also continue in the years to come as well.
